Atlas Trials

A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

Clinical trial NCT07628582 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07628582
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory B-cell Malignancies
Start date
2026-09-15
Primary completion
2028-10-30
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.